Aniqa Shahid,Signe MacLennan,Bradley R. Jones,Hanwei Sudderuddin,Zhong Dang,Kyle Cobarrubias,Maggie C. Duncan,Natalie N. Kinloch,Michael J. Dapp,Nancie M. Archin,Margaret A. Fischl,Igho Ofotokun,Adaora Adimora,Stephen Gange,Bradley Aouizerat,Mark H. Kuniholm,Seble Kassaye,James I. Mullins,Harris Goldstein,Jeffrey B. Joy,Kathryn Anastos,Zabrina L. Brumme,Ighovwerha Ofotokun,Anandi Sheth,Gina Wingood,Todd Brown,Joseph Margolick,Kathryn Anastos,David Hanna,Anjali Sharma,Deborah Gustafson,Tracey Wilson,Gypsyamber D’Souza,Stephen Gange,Elizabeth Topper,Mardge Cohen,Audrey French,Steven Wolinsky,Frank Palella,Valentina Stosor,Bradley Aouizerat,Jennifer Price,Phyllis Tien,Roger Detels,Matthew Mimiaga,Seble Kassaye,Daniel Merenstein,Maria Alcaide,Margaret Fischl,Deborah Jones,Jeremy Martinson,Charles Rinaldo,Mirjam-Colette Kempf,Jodie Dionne-Odom,Deborah Konkle-Parker,James B. Brock,Adaora Adimora,Michelle Floris-Moore,the MACS/WIHS combined cohort study (MWCSS)

Abstract:ABSTRACT Within-host HIV populations continually diversify during untreated infection, and this diversity persists within infected cell reservoirs during antiretroviral therapy (ART). Achieving a better understanding of on-ART proviral evolutionary dynamics, and a better appreciation of how the overall persisting pool of (largely genetically defective) proviruses differs from the much smaller replication-competent HIV reservoir, is critical to HIV cure efforts. We reconstructed within-host HIV evolutionary histories in blood from seven participants of the Women’s Interagency HIV Study who experienced HIV seroconversion, and used these data to characterize the diversity, lineage origins, and ages of proviral env-gp120 sequences sampled longitudinally up to 12 years on ART. We also studied HIV sequences emerging from the reservoir in two participants. We observed that proviral clonality generally increased over time on ART, with clones frequently persisting long term. While on-ART proviral integration dates generally spanned the duration of untreated infection, HIV emerging in plasma was exclusively younger (i.e., dated to the years immediately pre-ART). The genetic and age distributions of distinct proviral sequences remained stable during ART in all but one participant, in whom there was evidence that younger proviruses had been preferentially eliminated after 12 years on ART. Analysis of the gag region in three participants corroborated our env-gp120 -based observations, indicating that our observations are not influenced by the HIV region studied. Our results underscore the remarkable genetic stability of the distinct proviral sequences that persist in blood during ART. Our results also suggest that the replication-competent HIV reservoir is a genetically restricted, younger subset of this overall proviral pool. IMPORTANCE Characterizing the genetically diverse HIV sequences that persist in the reservoir despite antiretroviral therapy (ART) is critical to cure efforts. Our observations confirm that proviruses persisting in blood on ART, which are largely genetically defective, broadly reflect the extent of within-host HIV evolution pre-ART. Moreover, on-ART clonal expansion is not appreciably accompanied by the loss of distinct proviral lineages. In fact, on-ART proviral genetic composition remained stable in all but one participant, in whom, after 12 years on ART, proviruses dating to around near ART initiation had been preferentially eliminated. We also identified recombinant proviruses between parental sequence fragments of different ages. Though rare, such sequences suggest that reservoir cells can be superinfected with HIV from another infection era. Overall, our finding that the replication-competent reservoir in blood is a genetically restricted, younger subset of all persisting proviruses suggests that HIV cure strategies will need to eliminate a reservoir that differs in key respects from the overall proviral pool.

Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy

Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy

Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection

Immune activation and exhaustion marker expression on T-cell subsets in ART-treated adolescents and young adults with perinatal HIV-1 infection as correlates of viral persistence

The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection

Dynamics of HIV reservoir decay and naïve CD4 T-cell recovery between immune non-responders and complete responders on long-term antiretroviral treatment

Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART

HIV-1 diversity in viral reservoirs obtained from circulating T-cell subsets during early ART and beyond

Machine learning approaches identify immunologic signatures of total and intact HIV DNA during long-term antiretroviral therapy

Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease

[Dynamic changes of cellular HIV-1 DNA quantification during highly active antiretroviral therapy in Chinese HIV infected individuals]

Galectin-9 Levels as a Potential Predictor of Intact HIV Reservoir Decay

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy

Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration

The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial

Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells

Comparison of HIV DNA decay and immune recovery between early and chronic HIV-infected individuals 96 weeks after ART

The multifaceted nature of HIV tissue reservoirs

A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients